Navigation Links
TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials

e viral load (less than 50 copies/mL), compared with those in the placebo arm (39 percent; n=119) [p=0.005]. Similarly, in DUET-2, significantly more patients (62 percent; n=183) in the TMC125 arm achieved a confirmed undetectable viral load compared with those in the placebo arm (44 percent; n=129) [p=0.0003].

"The NNRTI class has been one of the cornerstones of antiretroviral therapy for more than a decade. However, NNRTI resistance limits the use of this class in treatment-experienced patients," said Tony Mills, MD, HIV specialist in private practice, Los Angeles, and assistant professor of clinical medicine, UCLA. "The results that we saw in DUET-1 and -2 in patients with documented NNRTI resistance are very exciting and suggest that in the future, we may have the ability to sequence NNRTIs in HIV treatment."

24-Week Safety Findings

In DUET-1, the most commonly reported adverse events (>=10%), regardless of causality, among patients in the TMC125 arm vs. placebo arm were rash (20 percent vs. 10 percent), nausea (14 percent vs. 12 percent), diarrhea (12 percent vs. 20 percent), headache (10 percent vs. 13 percent), nervous system disorders including headache, somnolence, dizziness, and memory impairment (15 percent vs. 20 percent), and psychiatric disorders including insomnia, anxiety, depression and nightmare (10 percent vs. 14 percent). In the TMC125 arm, 42 patients discontinued treatment for any reason vs. 56 patients in the placebo arm.

In DUET-2, the most commonly reported adverse events (>=10%), regardless of causality, among patients receiving TMC125 vs. placebo were rash (14 percent vs. 9 percent), diarrhea (18 percent vs. 20 percent), nausea (14 percent vs. 10 percent), injection site reaction (13 percent vs. 15 percent), headache (9 percent vs. 11 percent), fatigue (9 percent vs. 10 percent), nervous system disorders (15 percent vs. 17 percent) and psychiatric disorders (16 percent vs. 17 percent). In the TMC125 arm, 51 pati
'"/>




Page: 1 2 3 4

Related medicine technology :

1. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
5. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
6. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
7. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
8. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
9. Laquinimod, a Novel Oral Compound, Showed Significant Reduction in Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
10. OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer
11. Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
Post Your Comments:
(Date:8/28/2015)... , FARUM, Denmark and ... On July 31, 2015 the US Food and Drug Administration ... of Major Depressive Disorder in adult patients who have failed ... current episode. TMS is a non-invasive technique for stimulating neural ... suffering from Major Depressive Disorder. The procedure has been proven ...
(Date:8/28/2015)... Massachusetts y LONDRES, 28 de agosto ... AEX: PHIA) anunció hoy su participación en el  ... exhibirá sus soluciones cardiológicas más recientes y novedosas, ... Cardiovascular, que conectan a las personas y la ... de ayudar a diagnosticar, guiar los tratamientos y ...
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... Sept. 30 /PRNewswire-Asia/ -- Winner Medical Group Inc. ... leading manufacturer of medical dressings, medical disposables and ... products industries in China, today announced that it ... store at www.purcotton.com . Opening ...
... Announces Fourth Quarter and Fiscal Year 2010 Results -- LAIYANG, China, Sept. 30 /PRNewswire-Asia-FirstCall/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
Cached Medicine Technology:Winner Medical Launches Its Own PurCotton® B2C Website 2Winner Medical Launches Its Own PurCotton® B2C Website 3Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 2Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 3Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 4Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 5Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 6Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 7Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 8Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 9Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 10Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 11Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 12Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 13Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 14Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 15Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 16Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 17Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 18
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... Ultrasound (HIFU) medical devices for the treatment of prostate cancer, has announced the ... this summer at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® ...
(Date:8/29/2015)... ... 29, 2015 , ... "I have been a licensed physical ... specialize in manual therapy, and my invention will provide headache sufferers a solution ... muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates headaches, ...
(Date:8/29/2015)... ... August 29, 2015 , ... Next weekend is Labor ... (which astronomically, officially ends on September 22nd this year). For IT security personnel, it ... linger on which could prove far more costly than a simple headache. , Joe ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... freely market and sell Arterosil and Arterosil HP, and that all claims and ... sued Vascular Health Sciences, LLC (VHS) in the United States District Court for ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of ... for the position they are applying for, they are unable to pass the initial ... considering altering drug testing policies in order to be able to hire long-term, skilled ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4
... taking common antibacterial medication , THURSDAY, July 2 (HealthDay ... can cause sensorineural hearing loss, finds a new study. ... fibrosis patients treated over a 13-year period at Children,s ... them suffered from sensorineural hearing loss. Of those seven ...
... 2 Cardinal Health today announced that Bruce L. Downey ... completion of the planned spinoff of CareFusion Corporation, replacing John ... reasons after 22 years of service to the company as ... former chairman and chief executive officer of Barr Pharmaceuticals, Inc. ...
... ... contest for the best new industry application of its hand-centric motion capture and ... offers the most sophisticated hand-centric motion capture solutions in the marketplace. The winner ... free use for 12 months to develop their winning industry-application concept! , ...
... ,Help is Here Express, bus tour will be stopping in ... at various cities in order to help uninsured and ... medicines for free or nearly free. With the state,s unemployment ... year ago, the Partnership for Prescription Assistance (PPA) is ready ...
... , This release is available in Spanish ... of this kind of humour) favour the mental mechanisms which ... macho attitudes. Those are the conclusions of a study carried ... be released tomorrow Thursday 2nd of July in the framework ...
... SETO Holdings, Inc. (Pink Sheets: SETO) is pleased ... Virginia at 1244 Sycamore Sq. (Shopping Center), Midlothian (Richmond, VA). ... can go to ADVANCED,s web site (877allears.com) or contact Richard ... , , Forward-Looking Statements: Statements in this new ...
Cached Medicine News:Health News:Cardinal Health Appoints Bruce Downey to Board of Directors; John McCoy Retires From Board After 22 Years 2Health News:CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 2Health News:CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 3Health News:Partnership for Prescription Assistance Prepared to Help North Dakota Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help North Dakota Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help North Dakota Workers Hurt by Recession 4Health News:Sexist jokes favor the mental mechanisms that justify violence against women 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: